Good Morning America: New Report on the Effect of Weight Loss Drugs on Heart Disease

A new study found patients with obesity-related heart failure and diabetes had a significant improvement in symptoms when taking semaglutide.

The findings of the STEP-HFpEF DM trial, led by Dr. Mikhail Kosiborod, cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, were announced over the weekend at the American College of Cardiology Scientific Session.

Good Morning America discussed the study's findings below.

Related Content

Apr. 8, 2024
CNN: Weight-Loss Drug Wegovy Offers Benefits for People with Diabetes and Common Form of Heart Failure, Study Finds
The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.
Apr. 6, 2024
Semaglutide 2.4 mg Demonstrates Large Reductions in Heart Failure Related Symptoms and Physical Limitations in People with Obesity-Related Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes
Saint Luke’s Mid America Heart Institute today announced results from the STEP HFpEF DM trial.